Chemycal has been acquired by 3E

Learn More
  • November 9, 2022
  • EFSA

Workshop on EFSA’s updated Guidance on the use of the benchmark dose approach in risk assessment | Event on: 15-16 February 2023

Your substances


EFSA’s Scientific Committee first developed guidance on the use of the BMD approach in EFSA’s risk assessments as an alternative to the traditional No-Observed-Adverse-Effect-Level (NOAEL) approach, in 2009. A 2017 update mainly concerned how to apply the BMD approach in practice and model averaging was introduced to account for model uncertainty. Following an EFSA workshop in March 2017 to discuss commonalities and divergences in the various approaches for BMD analysis worldwide, and the update of Chapter 5 on dose– response assessment of WHO/IPCS Environmental Health Criteria 240 (WHO, 2020), the Scientific Committee decided to update its guidance again to align it with internationally agreed concepts related to benchmark dose analysis, introducing Bayesian model averaging and a harmonised set of dose-response models for continuous and quantal responses, further harmonising EFSA’s approach with its partners.



Related News